(MENAFN- financial News Media) NetworkNewsWire Editorial Coverage
New York, NY – October 3, 2024 – Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs. This strategic approach holds promise for providing hope to millions of patients suffering from historically challenging diseases. Alzheimer's disease (AD) for example, has become a focal point of this innovation, with recent U.S. Food and Drug Administration (FDA) approvals of Leqembi and Kisunla - although these treatments only slow cognitive decline rather than improve cognitive function. New uses for approved glucagon-like peptide-1 (GLP-1) and phosphodiesterase 5 (PDE5) inhibitor drugs show promise in treating Alzheimer's, with companies such as Annovis Bio Inc. (NYSE: ANVS) (profile ) leading the way with treatments ready for late-stage clinical trials. Beyond Alzheimer's, the pharmaceutical industry is experiencing a surge of innovation across various disease areas. Major players, including Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK) and GSK plc (NYSE: GSK) are at the forefront of medical innovation, tackling previously intractable diseases.
Annovis is leading the way in the development of buntanetap, currently testing the drug in pivotal clinical trials for Alzheimer's and Parkinson's diseases.
The company has secured intellectual property for innovative combination therapies involving buntanetap and other drugs, including Trulicity(R) and Viagra(R), which work together to enhance cognitive function.
Annovis' planned phase 3 studies may evaluate both double combinations (buntanetap with GLP-1 agonist or PDE5 inhibitor) and a triple combination of all three drugs.
Click here to view the custom infographic of the Annovis Bio editorial.
Buntanetap Targeting Alzheimer's Disease
Annovis Bio Inc. (NYSE: ANVS) is leading efforts to develop innovative and safe treatments for neurodegenerative diseases such as Alzheimer's. The company's main focus is enhancing nerve cell health to improve cognition in such conditions, a target that has proved elusive for peers. The company's flagship drug candidate, buntanetap, has completed advanced-stage clinical trials for both AD and Parkinson's disease (PD) and has shown compelling results in both indications.
Earlier in the year, Annovis shared positive data from a phase 2/3 trial evaluating buntanetap as an oral therapy for early-stage AD. This trial, which included 353 participants, assessed both the drug's effectiveness alongside standard care, as well as providing insight on the safety profile. The results demonstrated cognitive improvements across all doses compared to placebo, with the 30mg dose showing the greatest benefit, measured by the ADAS-Cog 11 scale. These findings aligned with prior studies (NCT04524351 , NCT02925650 ), with buntanetap also reducing key disease biomarkers including neurofilament light (NFL), tau protein and the inflammatory biomarker glial fibrillary acidic protein (GFAP). Annovis is currently planning for a confirmatory phase 3 trial in biomarker-positive early AD patients to support an anticipated New Drug Application (NDA) submission.
Recently, Annovis expanded its approach by exploring combinations of buntanetap with drugs such as Trulicity (dulaglutide) and Viagra (sildenafil), either as individual combination therapies or a three-prong approach utilizing all for their unique strengths. The three drugs bring their own strengths to the combination table. Trulicity, a popular GLP-1 agonist, has been shown to improve brain glucose metabolism. Viagra is known to enhance cerebral blood flow. Buntanetap inhibits the production of neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP-43, and improves the flow of information, offering a potential to restore cognitive function in patients.
Next-Generation AD Opportunity
Annovis recently unveiled preclinical data demonstrating that combining buntanetap with Trulicity in an Alzheimer's mouse model yielded synergistic benefits. While both drugs individually improved cognitive function, their combined impact surpassed that of healthy controls by 16%, reinforcing the potential of combination therapies for AD treatment.
It is theorized that the improvement as a combination is undergirded by the neurotoxic inhibiting attributes of buntanetap paired with Trulicity's ability to penetrate the blood-brain barrier and normalize glucose metabolism. This groundbreaking research marks the first instance of a treatment restoring cognitive function beyond normal levels.
“We are excited to see that buntanetap significantly amplifies the effects of dulaglutide on memory and learning, with a 6- to 10-fold increase in efficacy,” said Annovis Bio founder, president and CEO Maria Maccecchini, PhD, regarding the study results.
A Fresh Perspective on an Old Problem
The fight against neurodegenerative disease potentially could get a boost from unexpected sources, as drugs traditionally used for diabetes and erectile dysfunction (ED) are used for AD.
GLP-1 Agonists
Originally designed to treat type 2 diabetes, these drugs (such as semaglutide and liraglutide) mimic a hormone that regulates blood sugar. While helping diabetics control glucose, researchers noticed an additional benefit: significant weight loss. This led to the approval of drugs such as Wegovy for obesity treatment that act by suppressing appetite and increasing fat burning.
The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing inflammation, improving brain's insulin sensitivity and enhancing neuroplasticity (the brain's ability to form new connections).
Early clinical trials are promising. Mid-stage data showed Liraglutide (Victoza), a GLP-1 drug, to significantly minimized brain shrinkage in memory, learning and language areas compared to a placebo.
PDE5 Inhibitors
These medications (such as Viagra and Cialis), known for treating ED where smooth muscle contraction is paramount, are also being explored for AD. Although commonly used for their blood pressure-lowering effects, preclinical studies suggest they can improve synaptic function (communication between brain cells) and cerebral blood flow while also enhancing cognitive abilities. Currently, four oral PDE5 inhibitors are available in the United States: sildenafil (Viagra(R), Pfizer), vardenafil (Levitra/Staxyn(R), Bayer), tadalafil (Cialis(R), Eli Lilly), and avanafil (Stendra(R), Vivus).
Real-world data also paints a hopeful picture. Notably, sildenafil (Viagra) is linked to a reduced risk of dementia in patients who take it. Cleveland Clinic-led research discovered that in Alzheimer's patients, sildenafil reduces levels of neurotoxic tau proteins, known contributors to the disease. Additionally, neurons treated with sildenafil exhibited enhanced cell growth, improved brain function and reduced inflammation, all of which are crucial for protecting against the neural degeneration associated with Alzheimer's.
This promising research suggests both GLP-1 agonists and PDE5 inhibitors could have a neuroprotective effect, offering a new approach to combatting AD. By targeting the disease from multiple angles, these drugs hold potential for a more holistic treatment strategy.
Growing Patent Estate
Annovis has taken a proactive step to protect its intellectual property by filing three new patents for innovative combination therapies involving buntanetap. These patents encompass combinations with Trulicity and Viagra, as well as a synergistic approach using all three drugs. The combination of these drugs provides a competitive advantage to Annovis insomuch that buntanetap has completed phase 3 studies as a standalone treatment and the others are already FDA approved. To wit, Annovis is well positioned to initiate phase 3 clinical studies.
Further, this multifaceted approach offers unprecedented potential in combating neurodegeneration, especially considering the growing prevalence of AD in the U.S. Neurodegenerative diseases are on the rise, with Alzheimer's affecting nearly 6.7 million Americans today. Without significant medical breakthroughs, this number is projected to double to 13.8 million by 2060. With buntanetap already completing phase 3 trials and Trulicity and Viagra being FDA approved, these combination therapies are well positioned for further clinical development under the protection of Annovis' patents.
Other Innovators
A wave of innovative treatments is emerging, offering hope for patients with previously challenging conditions. The outlook is brightening as promising therapies are being developed, paving the way for a brighter future in healthcare.
Johnson & Johnson (NYSE: JNJ) , a multinational pharmaceutical, biotechnology, and medical technologies corporation, is focused on healthcare innovation that builds a world where complex diseases are prevented, treated and cured; and where treatments are smarter and less invasive; and solutions are personal. Most recently the company invested more than $2 billion in new, advanced technology manufacturing facility in North Carolina to support robust portfolio growth. The new facility will expand production of Johnson & Johnson's innovative biologic medicines in areas including oncology, immunology, and neuroscience; construction on the state-of-the-art structure is slated to begin in the first half of 2025.
Novartis (NYSE: NVS) is an innovative medicines company with research and development at its core. The company's R&D engine powers an industry-leading pipeline that is focused on delivering transformative medicines to fight disease, restore possibility and help people live life on their own terms. The company's researchers work across several diseases areas to drive drug discovery and early development, while its development organization leads the advanced clinical development of those medicines. This work is powered by technology platforms that help the company innovate across its core therapeutic areas: cardiovascular, renal and metabolic, oncology, immunology and neuroscience.
Merck & Co. Inc. (NYSE: MRK) is developing an investigational GLP-1/glucagon receptor co-agonist: efinopegdutide (MK-6024). The experimental drug efinopegdutide, which is being developed as a treatment for nonalcoholic steatohepatitis (NASH) and was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for this treatment, also showed a weight-loss benefit, said CEO Robert Davis during the 45th Annual Goldman Sachs Healthcare Conference.
GSK plc (NYSE: GSK) was at this year's Alzheimer's Association International Conference, presenting four new abstracts contributing to early science in neurodegenerative diseases. More specifically, GSK was presenting results from the ZOSTER-122 retrospective, observational matched-cohort study in adults aged 50 years and over, which examines the potential association between Shingrix (Recombinant Zoster Vaccine or RZV) vaccination and reduced risk of dementia compared to two other vaccines.
These pharmaceutical players are working to find effective treatments for diseases that for decades have been underserved. Potential breakthroughs in the development of new drugs could mean big success for these companies and, even more important, significant benefits for the individuals suffering from these diseases.
For more information about Annovis Bio Inc. (NYSE: ANVS), please visit Annovis Bio Inc.
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: /Disclaimer
NetworkNewsWire is powered by IBN
DISCLAIMER : NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with NNW or any company mentioned herein. The commentary, views and opinions expressed in this release by NNW are solely those of NNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW and FNM for any investment decisions by their readers or subscribers. NNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, FNM, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.
FNM & NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.“Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as“may”,“future”,“plan” or“planned”,“will” or“should”,“expected,”“anticipates”,“draft”,“eventually” or“projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.
NetworkNewsWire
New York, NY
212.418.1217 Office
...
SOURCE: NetworkNewsWire
MENAFN03102024000225011067ID1108744501